YOLFTbeta
ADM Korea Inc.

ADM Korea Inc.

187660 · KQ · Healthcare / Medical Care Facilities

6,240.00KRW+30.00 (+0.48%)

Price History

Full chart

Market Stats

Previous Close6,210.00
Open6,220.00
Day Range6,150.00 – 7,120.00
52-Week Range2,254.08 – 20,844.19
Volume1.38M
Market Cap477.15B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta2.32
50-Day Avg5,259.80
200-Day Avg7,271.84

About

Penetrium Bioscience Inc., a contract research organization, provides clinical-related professional services for customer requirements in South Korea. The company offers clinical development services, such as medical writing, clinical operation, late phase study, data management, biostatistics, and regulatory affairs. It also provides pharmacovigilance services, which include case processing and safety reporting, safety and risk management plans, aggregate reporting, literature screening, and medical device vigilance; and quality assurance services. The company was formerly known as Hyundai ADM Bio Inc. and changed its name to Penetrium Bioscience Inc. in March 2026. Penetrium Bioscience Inc. was founded in 2003 and is based in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryMedical Care Facilities
  • CEOHyun-woo Kim
  • Employees0
  • Headquarters#603, 166 Magokdong-ro, Seoul, South Korea, 07790, Korea
  • Websitehttps://penetriumbio.com

Leadership

  • Hyun-woo KimCEO & Director · b. 1977
  • Mr. Seokmin YoonFounder & President
  • Mr. Dohyeong NaChief Financial officer
  • Ms. Mihyun ChoManaging Director

Financials

Income Statement

Currency: KRW2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue2.39B10.21B13.12B13.98B14.88B13.79B9.74B9.27B
Growth (%)-+327.23%+28.55%+6.54%+6.47%-7.34%-29.33%-4.84%
Cost of Revenue1.10B6.23B5.69B6.74B10.52B10.57B9.64B9.24B
Gross Profit1.29B3.98B7.43B7.24B4.37B3.22B101.25M33.58M
Gross Margin53.83%38.97%56.59%51.76%29.33%23.32%1.04%0.36%
Operating Expense1.19B3.13B3.89B5.14B5.12B5.13B16.08B7.41B
Operating Income99.83M850.88M3.53B2.09B-754.74M-1.91B-15.98B-7.38B
Operating Margin4.18%8.34%26.91%14.96%-5.07%-13.86%-163.97%-79.55%
EBITDA----1.67B538.92M-15.47B-11.82B
EBITDA Margin----11.23%3.91%-158.79%-127.52%
Net Income484.32M764.23M3.77B1.92B266.50M-2.97B-20.10B-14.83B
Net Income Margin20.27%7.49%28.77%13.75%1.79%-21.54%-206.22%-159.92%
R&D--727.77M627.73M587.01M569.66M10.73B2.12B
R&D as % of Total Revenue--5.55%4.49%3.94%4.13%110.06%22.91%
Interest Expense0019.44M52.82M509.01M756.73M1.17B1.78B
Interest Expense % of Total Revenue0.00%0.00%0.15%0.38%3.42%5.49%11.99%19.15%

Balance Sheet

Currency: KRW2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets8.55B16.45B20.74B38.36B46.29B44.21B28.53B32.79B
Total Liabilities4.75B5.56B6.39B4.78B15.95B17.09B21.70B11.27B
Total Equity3.81B10.89B14.34B33.59B30.34B27.15B6.82B21.53B
Cash3.05B3.39B8.57B5.27B3.10B3.37B5.78B4.78B
Total Debt--19.57M-----
Net Debt------2.46B219.59M

Cash Flow

Currency: KRW2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow581.00M1.27B5.32B738.21M903.74M-3.08B-14.29B-4.47B
Investing Cash Flow1.67B-6.53B-162.00M-20.53B-9.15B3.73B15.43B-
Financing Cash Flow-600.00M5.60B16.12M16.50B6.07B-374.26M1.27B-
Capital Expenditure062.13M75.87M1.10B1.57B624.88M96.71M773.19M
Free Cash Flow--5.24B-363.95M-668.31M-3.70B-14.39B-5.25B
FCF to OCF--98.42%-49.30%-73.95%120.30%100.68%117.28%

Earnings

Report DateJun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026
EPS Estimate--------------------
EPS Actual18.35-4.3012.454.18-0.44-0.29-6.85-12.63-9.13-17.97-24.68-31.18-278.69-79.62-59.28-81.6640.32-166.12-83.14-32.19
Surprise--------------------
Timing--------------------

Key Statistics & Ratios

Market Cap477.15B
Enterprise Value368.15B
Trailing P/E0.00
Forward P/E0.00
Price / Sales48.96
Price / Book15.84
Revenue (TTM)9.74B
Gross Profit (TTM)57.97M
EBITDA-14.41B
Profit Margin-206.22%
Operating Margin-164.13%
Return on Equity-88.95%
Return on Assets-27.49%
Shares Outstanding63.28M
Shares Float23.68M
Beta2.32
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Jun 29, 2026525:496
  • Nov 27, 20242:1